Intravitreal Bevacizumab (Avastin®) for Diabetic Retinopathy at 24-months: The 2008 Juan Verdaguer-Planas Lecture

E-ISSN： 1875-6417|6|5|313-322

ISSN： 1573-3998

Source： Current Diabetes Reviews, Vol.6, Iss.5, 2010-01, pp. : 313-322

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Intravitreal Bevacizumab for Diabetic Retinopathy

Current Diabetes Reviews, Vol. 5, Iss. 1, 2009-02 ,pp. : 39-46

Bentham Science Publishers

Access to resources Recommend Favorite

Intravitreal Triamcinolone in Diabetic Retinopathy

Current Diabetes Reviews, Vol. 5, Iss. 1, 2009-02 ,pp. : 18-25

Bentham Science Publishers

Access to resources Recommend Favorite

Intravitreal Anti-VEGF Drugs as Adjuvant Therapy in Diabetic Retinopathy Surgery

Current Diabetes Reviews, Vol. 7, Iss. 3, 2011-05 ,pp. : 176-184

Bentham Science Publishers

Access to resources Recommend Favorite

Genetics and Diabetic Retinopathy

Current Diabetes Reviews, Vol. 9, Iss. 1, 2013-01 ,pp. : 86-92

Bentham Science Publishers

Access to resources Recommend Favorite

Leukocytes in Diabetic Retinopathy

Current Diabetes Reviews, Vol. 3, Iss. 1, 2007-02 ,pp. : 3-14

Bentham Science Publishers

Access to resources Recommend Favorite